WEDNESDAY, May 25, 2022 (HealthDay News)
Physicians should be aware that prostate cancer increases the risk of serious and life-threatening blood clots in men by about 50 percent, researchers say.
All cancer patients are at increased risk of venous thromboembolism (VTE)a dangerous but treatable blood clot in the veins that is a leading cause of death in cancer patients.
Prostate cancer is the most commonly diagnosed cancer in middle-aged and older men. Previous research has suggested that men with prostate cancer are two to three times more likely to develop VTE than those without cancer, the researchers noted in their study, published May 24 in the online journal. BMJ open.
In light of significant improvements in prostate cancer care over the past decade, researchers wanted to reassess the risk of VTE in patients with prostate cancer.
The greatest risk of VTE is in the first six months after diagnosis of prostate cancer, they found.
“Physicians treating men with prostate cancer should be aware of the markedly increased risk of VTE in these men, particularly during the first six months following cancer diagnosis, to ensure a rapid VTE diagnosis,” said Yanina Lenz, of Bayer AG in Berlin, Germany. and his colleagues wrote.
Investigators analyzed 2007-2017 data from Sweden to assess VTE rates in more than 92,000 men with prostate cancer and a comparison group of more than 466,000 men without the disease.
They found that 3.2% of prostate cancer patients developed VTE within about five years of their cancer diagnosis, compared with 2.1% of men in the comparison group.
This means that about seven in 1,000 men with prostate cancer would develop a VTE each year, compared to about four in 1,000 men without prostate cancer.
After taking into account other factors that may affect VTE risk, such as heart disease and income, the researchers concluded that patients with prostate cancer had a 50% higher risk of VTE. higher within five years of their cancer diagnosis than those of the same age without prostate cancer.
“The magnitude of increased risk of VTE in men with prostate cancer observed in our study is lower than that observed for other types of cancer, as observed in previous studies, and is likely attributable to the high proportion of men with localized disease and low risk of cancer progression,” Lenz and colleagues said in a press release.
There’s more on VTE at US National Heart, Lung and Blood Institute.
THE SOURCE: BMJ openpress release, May 23, 2022
By Robert Preidt Health Day Journalist
Copyright © 2021 Health Day. All rights reserved.
See the slideshow